Cytoreductive nephrectomy: past, present and future

Myria Galazi; Alejo Rodriguez-Vida; Eleni Josephides; Noan-Minh Chau; Simon Chowdhury

doi:10.1586/14737140.2014.864240

Cytoreductive nephrectomy: past, present and future

Myria Galazi, Alejo Rodriguez-Vida, Eleni Josephides, Noan-Minh Chau, Simon Chowdhury^*

^*Corresponding author for this work

GSTT Guy's and St Thomas' NHS Foundation Trust

Research output: Contribution to journal › Literature review › peer-review

3 Citations (Scopus)

Abstract

Cytoreductive nephrectomy (CN) is an integral part of the treatment of patients with metastatic renal cell carcinoma. Improved survival has been shown with CN and IFN-alpha. The introduction of targeted therapy for metastatic renal cell carcinoma has raised important questions regarding the role of CN. The majority of patients who were enrolled in the Phase III studies of targeted therapies had undergone prior nephrectomy. Thus, the benefit of these agents has largely been demonstrated in a nephrectomized population. CARMENA and SURTIME, important Phase III studies examining the role and timing of CN, are ongoing. Until new evidence is available, CN is a reasonable approach in selected patients with a resectable primary tumor and good performance status.

Original language	English
Pages (from-to)	271-277
Number of pages	7
Journal	EXPERT REVIEW OF ANTICANCER THERAPY
Volume	14
Issue number	3
DOIs	https://doi.org/10.1586/14737140.2014.864240
Publication status	Published - Mar 2014

Keywords

cytoreductive nephrectomy
targeted therapy
CARMENA
SURTIME
tyrosine kinase inhibitor
RENAL-CELL CARCINOMA
BLIND PHASE-III
INTERFERON-ALPHA
PROGNOSTIC-FACTORS
RANDOMIZED-TRIAL
SURVIVAL
CANCER
SUNITINIB
SORAFENIB
THERAPY

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/14737140.2014.864240

Cite this

@article{9ad5625472a44473867a5239c7268231,

title = "Cytoreductive nephrectomy: past, present and future",

abstract = "Cytoreductive nephrectomy (CN) is an integral part of the treatment of patients with metastatic renal cell carcinoma. Improved survival has been shown with CN and IFN-alpha. The introduction of targeted therapy for metastatic renal cell carcinoma has raised important questions regarding the role of CN. The majority of patients who were enrolled in the Phase III studies of targeted therapies had undergone prior nephrectomy. Thus, the benefit of these agents has largely been demonstrated in a nephrectomized population. CARMENA and SURTIME, important Phase III studies examining the role and timing of CN, are ongoing. Until new evidence is available, CN is a reasonable approach in selected patients with a resectable primary tumor and good performance status.",

keywords = "cytoreductive nephrectomy, targeted therapy, CARMENA, SURTIME, tyrosine kinase inhibitor, RENAL-CELL CARCINOMA, BLIND PHASE-III, INTERFERON-ALPHA, PROGNOSTIC-FACTORS, RANDOMIZED-TRIAL, SURVIVAL, CANCER, SUNITINIB, SORAFENIB, THERAPY",

author = "Myria Galazi and Alejo Rodriguez-Vida and Eleni Josephides and Noan-Minh Chau and Simon Chowdhury",

year = "2014",

month = mar,

doi = "10.1586/14737140.2014.864240",

language = "English",

volume = "14",

pages = "271--277",

journal = "EXPERT REVIEW OF ANTICANCER THERAPY",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "3",

}

TY - JOUR

T1 - Cytoreductive nephrectomy

T2 - past, present and future

AU - Galazi, Myria

AU - Rodriguez-Vida, Alejo

AU - Josephides, Eleni

AU - Chau, Noan-Minh

AU - Chowdhury, Simon

PY - 2014/3

Y1 - 2014/3

N2 - Cytoreductive nephrectomy (CN) is an integral part of the treatment of patients with metastatic renal cell carcinoma. Improved survival has been shown with CN and IFN-alpha. The introduction of targeted therapy for metastatic renal cell carcinoma has raised important questions regarding the role of CN. The majority of patients who were enrolled in the Phase III studies of targeted therapies had undergone prior nephrectomy. Thus, the benefit of these agents has largely been demonstrated in a nephrectomized population. CARMENA and SURTIME, important Phase III studies examining the role and timing of CN, are ongoing. Until new evidence is available, CN is a reasonable approach in selected patients with a resectable primary tumor and good performance status.

AB - Cytoreductive nephrectomy (CN) is an integral part of the treatment of patients with metastatic renal cell carcinoma. Improved survival has been shown with CN and IFN-alpha. The introduction of targeted therapy for metastatic renal cell carcinoma has raised important questions regarding the role of CN. The majority of patients who were enrolled in the Phase III studies of targeted therapies had undergone prior nephrectomy. Thus, the benefit of these agents has largely been demonstrated in a nephrectomized population. CARMENA and SURTIME, important Phase III studies examining the role and timing of CN, are ongoing. Until new evidence is available, CN is a reasonable approach in selected patients with a resectable primary tumor and good performance status.

KW - cytoreductive nephrectomy

KW - targeted therapy

KW - CARMENA

KW - SURTIME

KW - tyrosine kinase inhibitor

KW - RENAL-CELL CARCINOMA

KW - BLIND PHASE-III

KW - INTERFERON-ALPHA

KW - PROGNOSTIC-FACTORS

KW - RANDOMIZED-TRIAL

KW - SURVIVAL

KW - CANCER

KW - SUNITINIB

KW - SORAFENIB

KW - THERAPY

U2 - 10.1586/14737140.2014.864240

DO - 10.1586/14737140.2014.864240

M3 - Literature review

SN - 1473-7140

VL - 14

SP - 271

EP - 277

JO - EXPERT REVIEW OF ANTICANCER THERAPY

JF - EXPERT REVIEW OF ANTICANCER THERAPY

IS - 3

ER -

Cytoreductive nephrectomy: past, present and future

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this